Aryastha Lifesciences specializes in drug discovery and development services, harnessing the power of established cell line, primary cells from diseased organs, and in vivo models, including syngeneic and cell/tissue-derived systems. Our seamless integration of in vitro biology, in vivo pharmacology, and Drug Metabolism and Pharmacokinetics (DMPK) services offers robust support for drug discovery and early development endeavors. This integration and our expertise in discovery chemistry, CMC, and safety assessment enable us to successfully generate preclinical candidates and deliver comprehensive IND packages.
We use established cell lines from ATCC or other reputed organizations. These lines are very early passages free from common contamination like microplasma. This is mainly used for understanding the molecular pathway perturbation using developmental molecules in a high-throughput manner.
These cells are mainly derived from diseased tissues (rodents and humans). These cells provide more biologically relevant data than that established cell lines. At Aryastha, we have developed a faster way to generate primary cells of our interest, and these cells can be used in various applications, from basic research to drug discovery. These lines are combined with 3D cell culture technologies for better reagents/models to improve research. These cells are ethically sourced and authenticated by testing possible contamination and key disease-specific markers.
Here are disease indications of different species (mice and humans) for our primary cell’s capabilities. Tumor cells (Breast, Lungs, GBM, CRC, HNSCC, Ovarian, etc.), Immune Cells (microphases, dendritic cells), Heart, Liver, and Kidney Cells.
We have generated and developed primary cells-derived mouse models for oncology and non-oncology drug discovery- for efficacy, pharmacodynamic, and biomarker studies. We also use established cell lines derive murine model for PK/PD/Efficacy correlation. We have also developed syngeneic mouse models for drug discovery and development where both tumor/immune microenvironments are preserved.
We offer different in vitro and in vivo models mimicking the biology of human/rodent diseases. We use them to understand the biology, pathway perturbation, PK, and its correlation with target inhibition, efficacy, and meaningful understanding of possible biomarkers.
Oncology
Our oncology services offer advanced techniques including cancer cell panel screening, cell proliferation studies (CellTiter Glo), 3D culture assays, apoptosis analysis, and target validation (shRNA, RNAi, Crispr-Cas9). Additionally, we provide characterization of cell/animal models through whole exome and RNAseq analyses. Our comprehensive approach enables significant progress in cancer research.
Metabolic Disorder
In the realm of metabolic disorder research, our services encompass GSIS (Intact islet/pancreatic beta cell) assessments, fatty acid synthesis and oxidation assays, TCA cycle evaluations, glucose uptake studies, and the detection of TG, glycogen, and ketone bodies. Our comprehensive capabilities facilitate insightful discoveries in the field of metabolic disorders.
Immunology
Our immunology services encompass diverse techniques, including cytokine/chemokine profiling, T cell activation/proliferation, B cell and NK cell activation, ADCC, and immune cell co-culture with tumor cells. We specialize in PD1/PD-L1 binding assays, immune checkpoint evaluations, and immune reporter cells. Our offerings extend to engineered cel
